

Clinical trials of coumadin

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
coumadin vs control (on top of aspirin)			
ASPECT-2 (coumadin+ASA vs ASA) , 2002 n=298/289 follow-up: 1 year	coumadin(INR mean 2.4) +aspirin versus aspirin	Acute MI, unstable angina	Parallel groups open the Netherlands
coumadin vs placebo			
ASPECT , 1994 n=1700/1704 follow-up: 37 months (range 6-76)	nicoumalone or phenprocoumon, target INR 2.84.8 versus placebo	hospital survivors of myocardial infarction	Parallel groups double blind
coumadin vs aspirin			
ASPECT-2 (coumadin alone) , 2002 n=325/336 follow-up: 1 year (range 0-26 months)	coumadin (phenprocoumon or acenocoumarol) target INR 3-4 versus aspirin 80mg daily	Acute MI, unstable angina	Parallel groups open the Netherlands

More details and results :

- antithrombotics for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q36>
- anticoagulant for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q172>

References

ASPECT-2 (coumadin+ASA vs ASA), 2002:

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13 [[12126819](#)]

ASPECT, 1994:

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994;343:499-503 [[7906757](#)]

ASPECT-2 (coumadin alone), 2002:

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13 [12126819]

2 post myocardial infarction

Trial	Treatments	Patients	Trials design and methods
coumadin vs control (on top of aspirin)			
ASPECT-2 (coumadin+ASA vs ASA), 2002 n=298/289 follow-up: 1 year	coumadin(INR mean 2.4) +aspirin versus aspirin	Acute MI, unstable angina	Parallel groups open the Netherlands
coumadin vs placebo			
ASPECT, 1994 n=1700/1704 follow-up: 37 months (range 6-76)	nicoumalone or phenprocoumon, target INR 2.84.8 versus placebo	hospital survivors of myocardial infarction	Parallel groups double blind
coumadin vs aspirin			
ASPECT-2 (coumadin alone), 2002 n=325/336 follow-up: 1 year (range 0-26 months)	coumadin (phenprocoumon or acenocoumarol) target INR 3-4 versus aspirin 80mg daily	Acute MI, unstable angina	Parallel groups open the Netherlands

More details and results :

- anticoagulant for post myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q173>

References

ASPECT-2 (coumadin+ASA vs ASA), 2002:

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13 [12126819]

ASPECT, 1994:

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994;343:499-503 [7906757]

ASPECT-2 (coumadin alone), 2002:

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13 [12126819]

3 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
coumadin low dose vs coumadin standard dose			
PATAF (coumadin low dose vs coumadin standard dose) , 1999 n=122/131 follow-up: 2.7 years	coumarin low dose(target INR 1.1-1.6) versus coumarin standard dose(target INR 2.5-3.5)	non rheumatic AF,recruited in general practice,with no established indication for anticoagulation.	Parallel groups Simple aveugle Netherlands
triflusal+coumadin medium dose vs coumadin standard dose			
NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose) , 2004 n=235/237 follow-up: 2.76 years	Triflusal 600 mg/d + coumadin medium dose (target INR 1.25-2) versus coumadin standard dose(target INR 2-3)	Non valvular atrial fibrillation. Intermediate risk patients.	Parallel groups Open Spain
triflusal+coumadin medium dose vs triflusal			
NASPEAF (triflusal+coumadin medium dose vs triflusal) , 2004 n=235/242 follow-up: 2.76 years	Triflusal 600 mg/d + coumadin medium dose (target INR 1.25-2) versus Triflusal 600 mg/d	Non valvular atrial fibrillation. Intermediate risk patients	Parallel groups Open Spain

More details and results :

- antithrombotics for atrial fibrillation in primary prevention of thromboembolic events at <http://www.trialresultscenter.org/go-Q57>

References

PATAF (coumadin low dose vs coumadin standard dose), 1999:

Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, van Ree JW, Knottnerus JA Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999 Oct 9;319:958-64 [10514159]

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004:

Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix L Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004 Oct 19;44:1557-66 [15489085]

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004:

Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix L Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004 Oct 19;44:1557-66 [15489085]

4 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
coumadin vs control (on top of aspirin)			
ASPECT-2 (coumadin+asp vs asp) , 2002 n=333/336 follow-up: 1 year	coumadin(INR mean 2.4) +aspirin versus aspirin	UA, AMI	open the Netherlands
coumadin vs aspirin			
ASPECT-2 (coumadin vs aspirin) , 2002 n=325/336 follow-up: 1 year (range 0-26 months)	coumadin (phenprocoumon or acenocoumarol) target INR 3-4) versus aspirin 80mg daily	UA, AMI	Parallel groups open the Netherlands

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- anticoagulant for acute coronary syndrome in All ACS (including AMI) at <http://www.trialresultscenter.org/go-Q167>
- anticoagulant for acute coronary syndrome in ACS (excluding AMI) at <http://www.trialresultscenter.org/go-Q168>

References

ASPECT-2 (coumadin+asp vs asp), 2002:

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13 [12126819]

ASPECT-2 (coumadin vs aspirin), 2002:

5 superficial thrombophlebitis

Trial	Treatments	Patients	Trials design and methods
coumadin vs low dose heparin			
Belcaro (coumadin vs low dose hep) , 1999 n=NA follow-up:	coumadin versus low-dose subcutaneous heparin	-	

More details and results :

- antithrombotics for superficial thrombophlebitis in superficial thrombophlebitis of the leg at <http://www.trialresultscenter.org/go-Q218>

References

Belcaro (coumadin vs low dose hep), 1999:

Entry terms: heparin, Heparin, Unfractionated Heparin, Heparinic Acid, Liquaemin, Sodium Heparin, Heparin Sodium, alpha-Heparin, alpha Heparin,